-+ 0.00%
-+ 0.00%
-+ 0.00%
Dyne says FDA accepts z-rostudirsen BLA for exon 51 Duchenne muscular dystrophy under priority review
Share
Listen to the news
Dyne says FDA accepts z-rostudirsen BLA for exon 51 Duchenne muscular dystrophy under priority review
  • Dyne Therapeutics’ BLA for z-rostudirsen in exon 51 Duchenne muscular dystrophy was accepted by the FDA for Priority Review.
  • PDUFA target action date set for Jan. 21, 2027; application seeks accelerated approval based on dystrophin as a surrogate endpoint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200730PRIMZONEFULLFEED9764513) on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending